Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccine
Cancer vaccine therapy is improved using genetically modified dendritic cells
May 10th, 2006
According to a study from Japan, cancer vaccine therapy improved using genetically modified dendritic cells (DCs) expressing tumor-associated antigen. "The T-helper 1 (Th1) immune reaction is most important in DC-based immunotherapy. Interleukin 12 (IL-12) and granulocyte macrophage colony-stimulating factor (GM-CSF) play a pivotal role in inducing Th1 and cytotoxic T lymphocyte (CTL) responses. "In this study, DCs expressing the natural tumor antigen gp70 of BALB/c-derived CT26 were adenovirally transduced with the IL-12 gene and/or GM-CSF gene, and it was examined whether vaccinations using these genetically engineered DCs can induce strong...
Source: Vaccine Weekly (2006-05-10)
|
